Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Engraftment of CAR-CD19 T Cells in CD19+ B-cell Malignancies
NCT02933775Phase 1Unknown
- Sponsor
- Renji Hospital
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CG3001 in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Renji Hospital. Primary endpoint: Study related adverse events at 24 weeks. Status: unknown.
02
Drugs
CG3001
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT02933775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933775.